Hanall Biopharma Co., Ltd. (KRX:009420)

South Korea · Delayed Price · Currency is KRW

64,600

+300 (0.47%)

At close: Aug 28, 2026

112.85% (1Y)

Market Cap	3.28T +112.0%
Revenue (ttm)	162.66B +8.4%
Net Income	-24.90B
EPS	-481.41
Shares Out	50.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	245,544
Open	63,900
Previous Close	64,300
Day's Range	63,700 - 65,900
52-Week Range	28,950 - 73,000
Beta	0.88
Analysts	Strong Buy
Price Target	93,666.67 (+45.0%)
Earnings Date	Aug 28, 2026

About Hanall Biopharma

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascul... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1973

Employees 304

Stock Exchange Korea Stock Exchange

Ticker Symbol 009420

Full Company Profile

Financial Performance

In 2025, Hanall Biopharma's revenue was 155.18 billion, an increase of 11.69% compared to the previous year's 138.94 billion. Losses were -5.56 billion, 208.0% more than in 2024.

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for 009420 stock is "Strong Buy." The 12-month stock price target is ₩93,667, which is an increase of 45.00% from the latest price.

Price Target

₩93,667

(45.00% upside)

Analyst Consensus: Strong Buy

Stock Forecasts